Reg­u­la­tors throw up an­oth­er hur­dle to Roche’s $4.3B Spark ac­qui­si­tion as ques­tions per­co­late over he­mo­phil­ia mar­ket dom­i­na­tion

Don’t look for Roche’s $4.3 bil­lion Spark $ONCE buy­out — an­nounced 7 months ago — to close any­time in the very near fu­ture.

The UK Com­pe­ti­tion and Mar­kets Au­thor­i­ty just opened a 2-week pub­lic com­ment pe­ri­od on the tie-up, look­ing for some opin­ions on the phar­ma gi­ant’s com­pet­i­tive po­si­tion if the deal goes through. 

In an an­nounce­ment to­day the CMA re­marked that they were so­lic­it­ing re­marks on “whether the cre­ation of that sit­u­a­tion may be ex­pect­ed to re­sult, in a sub­stan­tial less­en­ing of com­pe­ti­tion with­in any mar­ket or mar­kets in the Unit­ed King­dom for goods or ser­vices.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER